33.87 USD
▲-0.37+5.02%
盘后 32.27 +0.06%
2026-08-03
市值
$2.37B
市盈率
—
EPS
-3.14
股息率
—
52 周区间
19.56 – 36.60
成交量
250.54K
Beta
-2.34
目标价
47.33
52W 低 19.5652W 高 36.60
价格走势
公司简介
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a...